-
After 4 years, the intensive lifestyle intervention resulted in a greater likelihood of partial remission of type 2 diabetes.
-
The risk of hip fracture goes up for about 6 weeks immediately after older people start taking antihypertensives.
-
The FDA has approved bedaquiline, a first in class drug for the treatment of multidrug-resistant tuberculosis.
-
Neither physical therapy nor steroid injection improved primary outcomes of tennis elbow at 1 year; in fact, steroid injection was associated with worse outcome. Physical therapy was associated with some improvement in short-term outcomes and secondary measures.
-
Peripheral Artery Disease: Helping Patients to Walk the Walk; Long-Term Functional Outcomes After Localized Prostate Cancer Treatment; A Relationship Between Nocturia and Hypertension
-
Aspirin use and AMD risk; using NSAIDs and antihypertensive agents; and FDA actions.
-
The 12-lead ECG and lead II rhythm strip shown above were obtained from a 55-year-old man with chest pressure.
-
In this small pilot study of patients who sought help for insomnia, most of the awakenings were actually caused by sleep-disordered breathing.
-
The FDA has approved a new drug with a novel mechanism of action for the treatment of rheumatoid arthritis in patients intolerant to or who have had inadequate response to methotrexate. Tofacifinib is an oral Janus kinase (JAK) inhibitor and is marketed by Pfizer as Xeljanz.
-
A randomized, controlled trial showed that moderate doses of simvastatin or pravastatin resulted in reduced energy or exertional fatigue in up to 40% of patients, especially in women.
